{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:47:51Z","timestamp":1785768471326,"version":"3.56.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s11906-018-0819-5","type":"journal-article","created":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T05:40:51Z","timestamp":1521438051000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome"],"prefix":"10.1007","volume":"20","author":[{"given":"Badhma","family":"Valaiyapathi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Calhoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,19]]},"reference":[{"issue":"5","key":"819_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/jhh.2011.47","volume":"26","author":"T Dudenbostel","year":"2012","unstructured":"\u2022\u2022 Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnoea and aldosterone. Journal of Human Hypertension. 2012;26(5):281\u20137. This reference is important since the review gives a detailed overview of existing literature and the shortcomings in the association between aldosterone, OSA and RHTN. https:\/\/doi.org\/10.1038\/jhh.2011.47 .","journal-title":"Journal of Human Hypertension"},{"key":"819_CR2","doi-asserted-by":"crossref","unstructured":"Vogt B, Bochud M, Burnier M. The association of aldosterone with obesity-related hypertension and the metabolic syndrome. In: Seminars in nephrology 2007 Sep 30 (Vol. 27, no. 5, pp. 529-537). WB Saunders.","DOI":"10.1016\/j.semnephrol.2007.07.009"},{"issue":"4","key":"819_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s11906-010-0126-2","volume":"12","author":"A Tirosh","year":"2010","unstructured":"Tirosh A, Garg R, Adler GK. Mineralocorticoid receptor antagonists and the metabolic syndrome. Curr Hypertens Rep. 2010;12(4):252\u20137. https:\/\/doi.org\/10.1007\/s11906-010-0126-2 .","journal-title":"Curr Hypertens Rep"},{"key":"819_CR4","unstructured":"Gomez-Sanchez CE. What is the role of the adipocyte mineralocorticoid receptor in the metabolic syndrome?."},{"key":"819_CR5","unstructured":"Feliciano Pereira P, Priore SE, Bressan J. Aldosterone: a cardiometabolic risk hormone? Nutricion Hospitalaria. 2014;30(6)"},{"issue":"2","key":"819_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","volume":"65","author":"J Bauersachs","year":"2015","unstructured":"Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension. 2015;65(2):257\u201363. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.04488 .","journal-title":"Hypertension"},{"issue":"8","key":"819_CR7","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/jhh.2009.96","volume":"24","author":"K Gaddam","year":"2010","unstructured":"Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens. 2010;24(8):532\u20137. https:\/\/doi.org\/10.1038\/jhh.2009.96 .","journal-title":"J Hum Hypertens"},{"issue":"1","key":"819_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1467-789X.2009.00623.x","volume":"11","author":"MM Ibrahim","year":"2010","unstructured":"Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11(1):11\u20138. https:\/\/doi.org\/10.1111\/j.1467-789X.2009.00623.x .","journal-title":"Obes Rev"},{"issue":"12","key":"819_CR9","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1097\/00004872-200112000-00022","volume":"19","author":"AG Logan","year":"2001","unstructured":"Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, Niroumand M, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001;19(12):2271\u20137. https:\/\/doi.org\/10.1097\/00004872-200112000-00022 .","journal-title":"J Hypertens"},{"issue":"5","key":"819_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.5603\/EP.2013.0019","volume":"64","author":"A Prejbisz","year":"2013","unstructured":"\u2022 Prejbisz A, Florczak E, Klisiewicz A, Dobrowolski P, Janaszek-Sitkowska H, Biele\u0144 P, et al. Relationship between primary aldosteronism and obstructive sleep apnoea, metabolic abnormalities and cardiac structure in patients with resistant hypertension. Endokrynologia Polska. 2013;64(5):363\u20137. The study showed that PA was associated with more pronounced LVH, while OSA was associated with concentric remodeling among OSA patients with RHTN and PA.","journal-title":"Endokrynologia Polska"},{"key":"819_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/srep45241","volume":"7","author":"X Ke","year":"2017","unstructured":"Ke X, Guo W, Peng H, Hu C, Zhang H, Peng C, et al. Association of aldosterone excess and apnea-hypopnea index in patients with resistant hypertension. Sci Rep. 2017;7:45241. https:\/\/doi.org\/10.1038\/srep45241 .","journal-title":"Sci Rep"},{"issue":"1","key":"819_CR12","doi-asserted-by":"publisher","first-page":"e84362","DOI":"10.1371\/journal.pone.0084362","volume":"9","author":"A Barcel\u00f3","year":"2014","unstructured":"\u2022\u2022 Barcel\u00f3 A, Pi\u00e9rola J, Esquinas C, de la Pe\u00f1a M, Arqu\u00e9 M, Alonso-Fern\u00e1ndez A, et al. Relationship between aldosterone and the metabolic syndrome in patients with obstructive sleep apnea hypopnea syndrome: effect of continuous positive airway pressure treatment. PloS One. 2014;9(1):e84362. This study showed that aldosterone levels are associated with MS, suggesting that aldosterone excess might predispose or aggravate the metabolic and cardiovascular complications in OSA patients.","journal-title":"PloS One"},{"issue":"5","key":"819_CR13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.20452\/pamw.3410","volume":"126","author":"B Krasinska","year":"2016","unstructured":"\u2022\u2022 Krasinska B, Miazga A, Cofta S, Szczepaniak-Chichel L, Trafas T, Krasinski Z, et al. Effect of eplerenone on the severity of obstructive sleep apnea and arterial stiffness in patients with resistant arterial hypertension. Pol Arch Med Wewn. 2016;126(5):330\u20139. This reference is important as it provides a new insight for the treatment of OSA with MRAs. It showed that eplerenone therapy significantly reduced the severity of OSA and arterial stiffness in patients with RHTN and OSA","journal-title":"Pol Arch Med Wewn"},{"issue":"15","key":"819_CR14","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1001\/archinte.160.15.2289","volume":"160","author":"EO Bixler","year":"2000","unstructured":"Bixler EO, Vgontzas AN, Lin HM, Ten Have T, Leiby BE, Vela-Bueno A, et al. Association of hypertension and sleep-disordered breathing. Arch Intern Med. 2000 Aug 14;160(15):2289\u201395. https:\/\/doi.org\/10.1001\/archinte.160.15.2289 .","journal-title":"Arch Intern Med"},{"issue":"8","key":"819_CR15","doi-asserted-by":"publisher","first-page":"835","DOI":"10.5664\/jcsm.3946","volume":"10","author":"HK Walia","year":"2014","unstructured":"Walia HK, Li H, Rueschman M, Bhatt DL, Patel SR, Quan SF, et al. Association of severe obstructive sleep apnea and elevated blood pressure despite antihypertensive medication use. J Clin Sleep Med. 2014;10(8):835\u201343. https:\/\/doi.org\/10.5664\/jcsm.3946 .","journal-title":"J Clin Sleep Med"},{"issue":"19","key":"819_CR16","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1056\/NEJM200005113421901","volume":"342","author":"PE Peppard","year":"2000","unstructured":"Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000;342(19):1378\u201384. https:\/\/doi.org\/10.1056\/NEJM200005113421901 .","journal-title":"N Engl J Med"},{"issue":"15","key":"819_CR17","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1001\/archinte.1997.00440360178019","volume":"157","author":"T Young","year":"1997","unstructured":"Young T, Peppard P, Palta M, Hla KM, Finn L, Morgan B, et al. Population-based study of sleep-disordered breathing as a risk factor for hypertension. Arch Intern Med. 1997;157(15):1746\u201352. https:\/\/doi.org\/10.1001\/archinte.1997.00440360178019 .","journal-title":"Arch Intern Med"},{"issue":"20","key":"819_CR18","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1001\/jama.2012.3418","volume":"307","author":"JM Marin","year":"2012","unstructured":"Marin JM, Agusti A, Villar I, Forner M, Nieto D, Carrizo SJ, et al. Association between treated and untreated obstructive sleep apnea and risk of hypertension. JAMA. 2012;307(20):2169\u201376. https:\/\/doi.org\/10.1001\/jama.2012.3418 .","journal-title":"JAMA"},{"issue":"12","key":"819_CR19","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1164\/rccm.200712-1809OC","volume":"179","author":"GT O'Connor","year":"2009","unstructured":"O'Connor GT, Caffo B, Newman AB, Quan SF, Rapoport DM, Redline S, et al. Prospective study of sleep-disordered breathing and hypertension: the Sleep Heart Health Study. Am J Respir Crit Care Med. 2009;179(12):1159\u201364. https:\/\/doi.org\/10.1164\/rccm.200712-1809OC .","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"819_CR20","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1164\/rccm.201101-0130OC","volume":"184","author":"I Cano-Pumarega","year":"2011","unstructured":"Cano-Pumarega I, Dur\u00e1n-Cantolla J, Aizpuru F, Miranda-Serrano E, Rubio R, Mart\u00ednez-Null C, et al. Obstructive sleep apnea and systemic hypertension: longitudinal study in the general population: the Vitoria Sleep Cohort. Am J Respir Crit Care Med. 2011;184(11):1299\u2013304. https:\/\/doi.org\/10.1164\/rccm.201101-0130OC .","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"819_CR21","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1378\/chest.112.5.1253","volume":"112","author":"W Pankow","year":"1997","unstructured":"Pankow W, Nabe B, Lies A, Becker H, K\u00f6hler U, Kohl FV, et al. Influence of sleep apnea on 24-hour blood pressure. Chest. 1997;112(5):1253\u20138. https:\/\/doi.org\/10.1378\/chest.112.5.1253 .","journal-title":"Chest"},{"issue":"9594","key":"819_CR22","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0140-6736(07)61538-4","volume":"370","author":"J Boggia","year":"2007","unstructured":"Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Bj\u00f6rklund-Bodeg\u00e5rd K, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007;370(9594):1219\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(07)61538-4 .","journal-title":"Lancet"},{"issue":"8","key":"819_CR23","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1093\/ajh\/hpu023","volume":"27","author":"ES Muxfeldt","year":"2014","unstructured":"Muxfeldt ES, Margallo VS, Guimar\u00e3es GM, Salles GF. Prevalence and associated factors of obstructive sleep apnea in patients with resistant hypertension. Am J Hypertens. 2014;27(8):1069\u201378. https:\/\/doi.org\/10.1093\/ajh\/hpu023 .","journal-title":"Am J Hypertens"},{"issue":"2","key":"819_CR24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1378\/chest.06-1442","volume":"131","author":"MN Pratt-Ubunama","year":"2007","unstructured":"Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. CHEST J. 2007;131(2):453\u20139. https:\/\/doi.org\/10.1378\/chest.06-1442 .","journal-title":"CHEST J"},{"issue":"4","key":"819_CR25","first-page":"363","volume":"6","author":"CC Gonzaga","year":"2010","unstructured":"\u2022 Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding SM, et al. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine. 2010;6(4):363. The study confirmed a markedly high prevalence of OSA among RHTN patients. The study also showed that severity of OSA was greater in those patients with hyperaldosteronism and related to the degree of aldosterone excess","journal-title":"Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine"},{"issue":"2","key":"819_CR26","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1378\/chest.07-0311","volume":"132","author":"CB Bucca","year":"2007","unstructured":"Bucca CB, Brussino L, Battisti A, Mutani R, Rolla G, Mangiardi L, et al. Diuretics in obstructive sleep apnea with diastolic heart failure. CHEST J. 2007;132(2):440\u20136.","journal-title":"CHEST J"},{"issue":"3","key":"819_CR27","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1097\/HJH.0000000000000047","volume":"32","author":"T Kasai","year":"2014","unstructured":"Kasai T, Bradley TD, Friedman O, Logan AG. Effect of intensified diuretic therapy on overnight rostral fluid shift and obstructive sleep apnoea in patients with uncontrolled hypertension. J Hypertens. 2014 Mar 1;32(3):673\u201380. https:\/\/doi.org\/10.1097\/HJH.0000000000000047 .","journal-title":"J Hypertens"},{"issue":"4","key":"819_CR28","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S0895-7061(02)03267-3","volume":"16","author":"DS M\u00f8ller","year":"2003","unstructured":"M\u00f8ller DS, Lind P, Strunge B, Pedersen EB. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens. 2003 Apr 1;16(4):274\u201380. https:\/\/doi.org\/10.1016\/S0895-7061(02)03267-3 .","journal-title":"Am J Hypertens"},{"issue":"12","key":"819_CR29","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/sleep\/32.12.1589","volume":"32","author":"A Svatikova","year":"2009","unstructured":"Svatikova A, Olson LJ, Wolk R, Phillips BG, Adachi T, Schwartz GL, et al. Obstructive sleep apnea and aldosterone. Sleep. 2009 Dec 1;32(12):1589\u201392. https:\/\/doi.org\/10.1093\/sleep\/32.12.1589 .","journal-title":"Sleep"},{"issue":"8","key":"819_CR30","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0002-9149(86)90845-3","volume":"57","author":"AP Rocchini","year":"1986","unstructured":"Rocchini AP, Katch VL, Grekin R, Moorehead C, Anderson J. Role for aldosterone in blood pressure regulation of obese adolescents. Am J Cardiol. 1986 May 3;57(8):613\u20138. https:\/\/doi.org\/10.1016\/0002-9149(86)90845-3 .","journal-title":"Am J Cardiol"},{"issue":"1","key":"819_CR31","doi-asserted-by":"publisher","first-page":"F7","DOI":"10.1530\/JME-16-0025","volume":"57","author":"AN Cat","year":"2016","unstructured":"Cat AN, Friederich-Persson M, White A, Touyz RM. Adipocytes, aldosterone and obesity-related hypertension. J Mol Endocrinol. 2016;57(1):F7\u201321.","journal-title":"J Mol Endocrinol"},{"key":"819_CR32","doi-asserted-by":"crossref","unstructured":"\u2022 Urbanet R, Cat AN, Feraco A, Venteclef N, El Mogrhabi S, Sierra-Ramos C, De La Rosa DA, Adler GK, Quilliot D, Rossignol P, Fallo F. Adipocyte mineralocorticoid receptor activation leads to metabolic syndrome and induction of prostaglandin D2 synthase. Hypertension. 2015 . This study is important since it showed overactivation of MR in adipocytes participates in the development of MS, supporting the rationale for further clinical studies to evaluate the potential benefit of MRAs in patients with adipose tissue overexpressing MR, such as in obese individuals or those with MS.","DOI":"10.1161\/HYPERTENSIONAHA.114.04981"},{"issue":"1","key":"819_CR33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/MNH.0000000000000189","volume":"25","author":"JM Luther","year":"2016","unstructured":"Luther JM. Aldosterone in vascular and metabolic dysfunction. Curr Opin Nephrol Hypertens. 2016 Jan;25(1):16\u201321. https:\/\/doi.org\/10.1097\/MNH.0000000000000189 .","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"3","key":"819_CR34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11906-016-0626-9","volume":"18","author":"A Vecchiola","year":"2016","unstructured":"Vecchiola A, Lagos CF, Carvajal CA, Baudrand R, Fardella CE. Aldosterone production and signaling dysregulation in obesity. Curr Hypertens Rep. 2016;18(3):20. https:\/\/doi.org\/10.1007\/s11906-016-0626-9 .","journal-title":"Curr Hypertens Rep"},{"issue":"11","key":"819_CR35","doi-asserted-by":"publisher","first-page":"776","DOI":"10.7326\/0003-4819-150-11-200906020-00005","volume":"150","author":"JR Sowers","year":"2009","unstructured":"Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med. 2009 Jun 2;150(11):776\u201383. https:\/\/doi.org\/10.7326\/0003-4819-150-11-200906020-00005 .","journal-title":"Ann Intern Med"},{"issue":"5","key":"819_CR36","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.pcad.2009.12.004","volume":"52","author":"A Whaley-Connell","year":"2010","unstructured":"Whaley-Connell A, Johnson MS, Sowers JR. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis. 2010 Apr 30;52(5):401\u20139. https:\/\/doi.org\/10.1016\/j.pcad.2009.12.004 .","journal-title":"Prog Cardiovasc Dis"},{"issue":"9594","key":"819_CR37","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0140-6736(07)61538-4","volume":"370","author":"J Boggia","year":"2007","unstructured":"Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Bj\u00f6rklund-Bodeg\u00e5rd K, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007 Oct 12;370(9594):1219\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(07)61538-4 .","journal-title":"Lancet"},{"issue":"16","key":"819_CR38","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1056\/NEJM198104163041602","volume":"304","author":"ML Tuck","year":"1981","unstructured":"Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med. 1981 Apr 16;304(16):930\u20133.","journal-title":"N Engl J Med"},{"issue":"1","key":"819_CR39","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1183\/09031936.00166808","volume":"34","author":"P Levy","year":"2009","unstructured":"Levy P, Bonsignore MR, Eckel J. Sleep, sleep-disordered breathing and metabolic consequences. Eur Respir J. 2009;34(1):243\u201360.","journal-title":"Eur Respir J"},{"issue":"2","key":"819_CR40","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1210\/jc.2005-1733","volume":"91","author":"F Fallo","year":"2006","unstructured":"Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006 Feb 1;91(2):454\u20139. https:\/\/doi.org\/10.1210\/jc.2005-1733 .","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"819_CR41","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1161\/01.HYP.0000253258.36141.c7","volume":"49","author":"S Kidambi","year":"2007","unstructured":"Kidambi S, Kotchen JM, Grim CE, Raff H, Mao J, Singh RJ, et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension. 2007 Mar 1;49(3):704\u201311. https:\/\/doi.org\/10.1161\/01.HYP.0000253258.36141.c7 .","journal-title":"Hypertension"},{"issue":"2","key":"819_CR42","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1161\/01.HYP.0000231338.41548.fc","volume":"48","author":"M Bochud","year":"2006","unstructured":"Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F, et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006 Aug 1;48(2):239\u201345. https:\/\/doi.org\/10.1161\/01.HYP.0000231338.41548.fc .","journal-title":"Hypertension"},{"issue":"5","key":"819_CR43","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1530\/EJE-10-1074","volume":"164","author":"A Hannemann","year":"2011","unstructured":"Hannemann A, Meisinger C, Bidlingmaier M, D\u00f6ring A, Thorand B, Heier M, et al. Association of plasma aldosterone with the metabolic syndrome in two German populations. Eur J Endocrinol. 2011;164(5):751\u20138. https:\/\/doi.org\/10.1530\/EJE-10-1074 .","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"819_CR44","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1161\/CIRCULATIONAHA.107.708537","volume":"116","author":"E Ingelsson","year":"2007","unstructured":"Ingelsson E, Pencina MJ, Tofler GH, Benjamin EJ, Lanier KJ, Jacques PF, et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors. Circulation. 2007;116(9):984\u201392. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.708537 .","journal-title":"Circulation"},{"issue":"7","key":"819_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11906-015-0567-8","volume":"17","author":"R Garg","year":"2015","unstructured":"\u2022\u2022 Garg R, Adler GK. Aldosterone and the mineralocorticoid receptor: risk factors for cardiometabolic disorders. Curr Hypertens Rep. 2015;17(7):1\u20138. This reference summarizes the relationship between mineralocorticoid receptor and metabolic syndrome, and the role of MRAs in reducing the cardiovascular outcomes in patients with diabetes and obesity.","journal-title":"Curr Hypertens Rep"},{"key":"819_CR46","doi-asserted-by":"crossref","unstructured":"Buglioni A, Cannone V, Cataliotti A, Sangaralingham SJ, Heublein DM, Scott CG, Bailey KR, Rodeheffer RJ, Dess\u00ec-Fulgheri P, Sarzani R, Burnett JC. Circulating aldosterone and natriuretic peptides in the general community. Hypertension 2014 :HYPERTENSIONAHA-114.","DOI":"10.1161\/HYPERTENSIONAHA.114.03936"},{"issue":"4","key":"819_CR47","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1530\/EJE-10-1070","volume":"164","author":"M Sp\u00e4th","year":"2011","unstructured":"Sp\u00e4th M, Korovkin S, Antke C, Anlauf M, Willenberg HS. Aldosterone-and cortisol-co-secreting adrenal tumors: the lost subtype of primary aldosteronism. Eur J Endocrinol. 2011 Apr 1;164(4):447\u201355. https:\/\/doi.org\/10.1530\/EJE-10-1070 .","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"819_CR48","first-page":"564","volume":"36","author":"K Fujimoto","year":"2013","unstructured":"Fujimoto K, Honjo S, Tatsuoka H, Hamamoto Y, Kawasaki Y, Matsuoka A, et al. Primary aldosteronism associated with subclinical Cushing syndrome. J Endocrinol Investig. 2013;36(8):564\u20137.","journal-title":"J Endocrinol Investig"},{"issue":"5","key":"819_CR49","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3109\/10641963.2015.1131290","volume":"38","author":"L Yang","year":"2016","unstructured":"\u2022 Yang L, Zhang H, Cai M, Zou Y, Jiang X, Song L, et al. Effect of spironolactone on patients with resistant hypertension and obstructive sleep apnea. Clin Exp Hypertens. 2016;38(5):464\u20138. The study showed that spironolactone reduced the severity of OSA in RHTN patients with moderate to severe OSA in addition to reducing blood pressure.","journal-title":"Clin Exp Hypertens"},{"issue":"3","key":"819_CR50","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/dom.12224","volume":"16","author":"R Garg","year":"2014","unstructured":"Garg R, Kneen L, Williams GH, Adler GK. Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects. Diabetes Obes Metab. 2014 Mar 1;16(3):268\u201372. https:\/\/doi.org\/10.1111\/dom.12224 .","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"819_CR51","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1210\/jc.2006-0736","volume":"91","author":"C Catena","year":"2006","unstructured":"Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab. 2006;91(9):3457\u201363. https:\/\/doi.org\/10.1210\/jc.2006-0736 .","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"819_CR52","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","volume":"101","author":"CA Farquharson","year":"2000","unstructured":"Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101(6):594\u20137. https:\/\/doi.org\/10.1161\/01.CIR.101.6.594 .","journal-title":"Circulation"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-018-0819-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-018-0819-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-018-0819-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T21:31:18Z","timestamp":1751491878000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-018-0819-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["819"],"URL":"https:\/\/doi.org\/10.1007\/s11906-018-0819-5","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"19 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"23"}}